Overview INNA-051 Influenza Challenge Study Status: Not yet recruiting Trial end date: 2022-10-01 Target enrollment: Participant gender: Summary This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo. Phase: Phase 2 Details Lead Sponsor: ENA Respiratory Pty Ltd